| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 4,534 | 4,643 | ||
| Research and development | 6,127 | 6,232 | ||
| (gain) loss on fair value remeasurement of contingent consideration | 4,833 | -153 | ||
| Impairment of right-of-use assets | 1,411 | - | ||
| Total costs and expenses | 7,239 | 11,028 | ||
| Loss from operations | -7,239 | -11,028 | ||
| Interest income | 270 | 407 | ||
| Interest expense | 963 | 1,081 | ||
| Grant income | 480 | 547 | ||
| Other expense, net | -112 | - | ||
| Total other (expense) income | -325 | -127 | ||
| Net loss | -7,564 | -11,155 | ||
| Earnings per share, basic | -1.07 | -1.71 | ||
| Earnings per share, diluted | -1.07 | -1.71 | ||
| Weighted average number of shares outstanding, basic | 7,042,457 | 6,513,108 | ||
| Weighted average number of shares outstanding, diluted | 7,042,457 | 6,513,108 | ||
KALA BIO, Inc. (KALA)
KALA BIO, Inc. (KALA)